384 related articles for article (PubMed ID: 37462667)
1. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
5. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
[TBL] [Abstract][Full Text] [Related]
6. Healthcare costs of colorectal cancer screening and events following colonoscopy among commercially insured average-risk adults in the United States.
Fisher DA; Princic N; Miller-Wilson LA; Wilson K; Limburg P
Curr Med Res Opin; 2022 Mar; 38(3):427-434. PubMed ID: 34918589
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
[TBL] [Abstract][Full Text] [Related]
8. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
[TBL] [Abstract][Full Text] [Related]
9. Costs of colorectal cancer screening with colonoscopy, including post-endoscopy events, among adults with Medicaid insurance.
Fisher DA; Princic N; Miller-Wilson LA; Wilson K; Limburg P
Curr Med Res Opin; 2022 May; 38(5):793-801. PubMed ID: 35243953
[TBL] [Abstract][Full Text] [Related]
10. Barriers to utilization of three colorectal cancer screening options - Data from a national survey.
Zhu X; Parks PD; Weiser E; Jacobson DJ; Limburg PJ; Finney Rutten LJ
Prev Med Rep; 2021 Dec; 24():101508. PubMed ID: 34401220
[TBL] [Abstract][Full Text] [Related]
11. National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences.
Zhu X; Parks PD; Weiser E; Fischer K; Griffin JM; Limburg PJ; Finney Rutten LJ
Cancer Prev Res (Phila); 2021 May; 14(5):603-614. PubMed ID: 33888515
[TBL] [Abstract][Full Text] [Related]
12. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
13. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
[No Abstract] [Full Text] [Related]
14. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
Prince M; Lester L; Chiniwala R; Berger B
World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
[TBL] [Abstract][Full Text] [Related]
15. Colorectal cancer screening uptake and adherence by modality at a large tertiary care center in the United States: a retrospective analysis.
Cheney C; Parish A; Niedzwiecki D; Oko C; Walters C; Halpern D; Helmueller L; Hoyek NE; Miller-Wilson LA; Sullivan BA
Curr Med Res Opin; 2024 Mar; 40(3):431-439. PubMed ID: 38197407
[TBL] [Abstract][Full Text] [Related]
16. Incident colorectal cancer screening and associated healthcare resource utilization and Medicare cost among Medicare beneficiaries aged 66-75 years in 2016-2018.
Li S; Miller-Wilson LA; Guo H; Hoover M; Fisher DA
BMC Health Serv Res; 2022 Oct; 22(1):1228. PubMed ID: 36192728
[TBL] [Abstract][Full Text] [Related]
17. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
Berger BM; Parton MA; Levin B
Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
[TBL] [Abstract][Full Text] [Related]
18. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
Pickhardt PJ; Correale L; Hassan C
AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913
[No Abstract] [Full Text] [Related]
19. Colorectal cancer screening completion: An examination of differences by screening modality.
Finney Rutten LJ; Jacobson DJ; Jenkins GD; Fan C; Weiser E; Parks P; Doroshenk M; Limburg PJ; St Sauver JL
Prev Med Rep; 2020 Dec; 20():101202. PubMed ID: 32995145
[TBL] [Abstract][Full Text] [Related]
20. Utilization of a Colorectal Cancer Screening Test Among Individuals With Average Risk.
Fisher DA; Princic N; Miller-Wilson LA; Wilson K; Fendrick AM; Limburg P
JAMA Netw Open; 2021 Sep; 4(9):e2122269. PubMed ID: 34473259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
